FINDINGS:
Comparison: 2023-06-17.
Lungs: No focal consolidation or suspicious pulmonary nodules. No pneumothorax.
Mediastinum: Cardiomediastinal contours within normal limits.
Pleura/Pleural spaces: No pleural effusion or pleural thickening. no pleural nodularity.
Great vessels/Aorta: No thoracic aortic aneurysm or dissection.
Liver: 61 mm lobulated hepatic mass in segment 3 of the liver (hypoenhancing). No focal hepatic lesions. Normal attenuation.
Spleen: Normal in size and attenuation. No focal splenic lesion. accessory spleen.
Pancreas: Normal pancreatic contour and enhancement. No focal mass. no pancreatic mass.
Adrenal glands: Adrenal glands are normal without nodules.
Kidneys: No hydronephrosis. No enhancing renal mass.
GI tract/Bowel: No obstructive process. No focal bowel wall mass identified. nonspecific fluid levels. diverticulosis. stomach is normal.
Mesentery/Omentum: No ascites. No omental caking.
Mesenteric vessels (SMA/SMV): SMA/SMV are patent without thrombosis.
Urinary bladder: Unremarkable.
Reproductive organs: No adnexal mass. Uterus/prostate within expected size for age. prostate is normal / no prostatic mass.
Lymph nodes: Enlarged porta hepatis lymph node, short axis 22 mm. No pathologically enlarged lymph nodes by size criteria.
Bones/Osseous structures: No aggressive osseous lesion. No acute fracture.

IMPRESSION:
- Liver primary malignancy at segment 3 of the liver measuring approximately 61 mm.
- Findings concerning for nodal involvement.
- No definite distant metastases identified.
- RECIST 1.1 Summary:
- Target lesions (n=2; ≤2 per organ rule applied).
  • T1: Primary — 65→61 mm (longest diameter).
  • T2: Lymph node — 24→22 mm (short axis).
- SLD baseline: 89 mm.
- SLD current: 83 mm (-6.7% change).
- New lesions: absent (unequivocal).
- - RECIST 1.1 overall response category: PD.
